Eran Broshy - 26 Nov 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: Director
Issuer ticker: TBPH
Reported as of: 26 Nov 2025
Net transaction value: -$447,920
SEC form: 4
Accepted by SEC: 01 Dec 2025, 19:02:51 UTC
Prior SEC filing: 14 Nov 2025
Next SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Corinna Liebowitz, Attorney-in-Fact

Key filing fact

Eran Broshy filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 01 Dec 2025.

Key facts

This page summarizes Eran Broshy's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Dec 2025, 19:02.

Change

Previous filing in this sequence was filed on 14 Nov 2025.
Current net transaction value: -$447,920.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001256230 Primary reporting owner

BROSHY ERAN

Relationship: Director
Address: C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Corinna Liebowitz, Attorney-in-Fact
Signature date: 01 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Sale

Transaction value: $280,000
Shares: -14,000
Change %: -19%
Price: $20.00
Shares after: 60,204
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F1

TBPH transaction

Ordinary Shares

Sale

Transaction value: $310,020
Shares: -15,501
Change %: -26%
Price: $20.00
Shares after: 44,703
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBPH transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value: $142,100
Shares: +14,000
Change %: +21%
Price: $10.15
Shares after: 81,749
Date: 26 Nov 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 14,000
Exercise price: $10.15
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

Footnote F2

The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

Footnote F3

This Share Option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

Footnote F4

Reflects solely exercisable, vested Share Options following reported transaction.